The Long Run with Luke Timmerman

Kevin Parker, CEO of Cartography Biosciences, reveals insights on discovering new cancer drug targets through innovative multi-omic tools. He shares his journey from a biologist in Pennsylvania to a leader in biotech, highlighting the personal drive behind his research. The discussion covers advancements in single-cell genomics, the challenges of drug discovery, and the potential impacts of targeted therapies on patient care. Parker emphasizes collaboration and strategic partnerships as key to navigating the complexities of cancer treatment innovation.

David Roblin, CEO of Relation Therapeutics, delves into the revolutionary use of multi-omic tools and machine learning in drug discovery. He discusses the power of collaboration within London's biotech scene and shares insights from his journey from clinical medicine to the pharmaceutical industry. Roblin highlights the importance of teamwork, the impact of non-coding DNA on disease understanding, and how AI integration is transforming drug development. His fascinating perspective on interdisciplinary science and partnerships offers a glimpse into the future of biopharma innovation.

Andy Scharenberg, Co-founder and CEO of Umoja Biopharma, is advancing in vivo CAR-T cell therapies to make life-saving treatments more accessible. He talks about the challenges and breakthroughs in CAR T-cell treatments, including the transformative possibilities of gene therapies. Scharenberg reflects on his journey from medicine to molecular innovation and highlights the importance of collaboration in tackling complex immune disorders. He also shares exciting developments aimed at revolutionizing cancer treatment and enhancing patient outcomes.

Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.

Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.

Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.

Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.

David Schenkein, a general partner at GV and a seasoned hematologist, shares insights from his journey in biotech. He discusses the importance of company culture and how his diverse background shaped his investment philosophy. Schenkein emphasizes embracing failure as a vital part of innovation and reveals the interplay between AI and drug discovery. He reflects on his transition from CEO to venture capitalist, underlining the need for diverse strategies in investing. His vision focuses on patient outcomes and the transformative potential of biotech advancements.

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.